Objective: To assess patient attitudes to HSV-2 serotesting and the effect of providing detailed information regarding genital herpes, the blood test, and its implications. Methods: Consecutive genitourinary medicine clinic attenders were asked to complete an anonymous self administered questionnaire. Half received minimal additional information while the other half received a detailed information sheet.
Introduction
Two serotypes of herpes simplex virus (HSV) are recognised; both can cause cutaneous and mucocutaneous lesions, with the proportion attributable to HSV types 1 and 2 varying geographically. HSV-1 is common in the general population and often acquired non-sexually in childhood. HSV-2 is rarely a cause of oral lesions and serological evidence of HSV-2 is a good marker of genitally acquired infection.' Currently, diagnosis relies on viral culture from clinically visible lesions. Commercially available serological tests cannot distinguish between past infection with HSV-1 and infection with HSV-2. Reliable type specific assays are available in only a few centres on a research basis. Table 2 shows the proportion of patients wanting to know if they or their partners had been infected with genital herpes separated according to whether or not they received the additional information sheet. A small number of clinic attenders declined to answer the questionnaire. We have no data on the opinions of this group but we feel that it is unlikely to have significantly affected the validity of the results. Provision of a detailed information sheet did not significantly affect opinion, although borderline significance was reached with an increased number of participants receiving the information sheet wanting to know if their partner had been infected. This may suggest that much of the response is intuitive rather than reasoned judgment, although it would be important to know how much patients understood the complexity of the information provided. When piloting the information sheet with patients it was generally well received and understood by patients, although this was not formally tested. The questionnaire also asked if the information sheet answered all their questions; 85% said yes with few making any comments in the space provided. It would also be important to know whether detailed counselling or a "cooling off' period would have influenced decisions. Studies assessing screening for the cystic fibrosis gene for example, show that 70-95% accept offers of immediate testing whereas only 25% will make a return visit for such a test. 5 
